Prospective Observational Study Aimed at Evaluating Treatment Satisfaction and Effectiveness in Patients with Relapsing Multiple Sclerosis Starting CLADRibinE TAbLets (CLADREAL) First published 17/10/2022 Last updated 02/05/2024 EU PAS number:EUPAS49334 Study Ongoing